ASTRAZENECA APPOINTS DR SEAN BOHEN AS EXECUTIVE VICE PRESIDENT OF GLOBAL MEDICINES DEVELOPMENT AND CHIEF MEDICAL OFFICER AstraZeneca today announced the appointment of Sean Bohen MD, PhD, as Executive Vice President of Global Medicines Development and Chief Medical Officer. He will join the company on 15 September. Dr. Bohen will be responsible for driving the progress of AstraZeneca's portfolio of small molecules and biologics investigational medicines through late-stage development to regulatory approval. As Chief Medical Officer, he will be responsible for patient safety across the entire AstraZeneca and Medimmune portfolio. Dr. Bohen joins AstraZeneca from Genentech where he was most recently Senior Vice President of Early Development. He oversaw preclinical and clinical development programmes across all therapy areas, including oncology, respiratory and autoimmune diseases, to deliver trial-ready drug candidates to late-stage development. Before this, he held a number of positions in early and late-stage development, playing a key role in the growth and progress of the Genentech/Roche portfolio. Dr. Bohen was instrumental in bringing a large number of new medicines to patients, in particular for cancer, and led activities to incorporate diagnostics into clinical programmes. Prior to joining Genentech, Dr. Bohen was a Clinical Instructor in Oncology at Stanford University School of Medicine, a research associate at the Howard Hughes Medical Institute and a postdoctoral fellow at the National Cancer Institute. Pascal Soriot, Chief Executive Officer, said: "I'm delighted to welcome Sean to AstraZeneca at a very exciting time for our company. Our continued strategic investment in science is driving momentum across all therapy areas. Sean is a tremendous scientist and an accomplished drug developer. His impressive expertise in key areas of our exciting pipeline, including oncology and immunology, will further strengthen and accelerate the delivery of new medicines for patients. His extensive diagnostics experience will also reinforce our efforts in precision medicine." Dr. Bohen will be a member of AstraZeneca's Senior Executive Team, reporting into Pascal Soriot. He is a graduate of the University of Wisconsin-Madison and later earned his doctorate in biochemistry and his medical degree at the University of California, San Francisco. NOTES TO EDITORS To obtain a photograph of Dr. Bohen, please visit www.astrazeneca.com/media/photo-library or contact the global media relations team (details below). About AstraZeneca AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com CONTACTS Media Enquiries Esra Erkal-Paler UK/Global +44 20 7604 8030 Vanessa Rhodes UK/Global +44 20 7604 8037 Ayesha Bharmal UK/Global +44 20 7604 8034 Jacob Lund Sweden +46 8 553 260 20 Michele Meixell US +1 302 885 2677 Investor Enquiries UK Thomas Kudsk Larsen +44 20 7604 8199 +44 7818 524185 Eugenia Litz RIA +44 20 7604 8233 +44 7884 735627 Nick Stone CVMD +44 20 7604 8236 +44 7717 618834 Karl Hård Oncology +44 20 7604 8123 +44 7789 654364 Craig Marks ING +44 20 7604 8591 +44 7881 615764 Christer Gruvris +44 20 7604 8126 +44 7827 836825 US Dial / Toll-Free +1 301 398 3251 +1 866 381 7277 Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and Metabolic Disease, ING - Infection, Neuroscience and Gastrointestinal 24 August 2015 -ENDS-
AstraZeneca appoints Dr Sean Bohen
| Source: AstraZeneca PLC
Attachments
